Gilead Sciences, Inc. (GILD) 10-Year Financial Performance & Capital Metrics

GILD • • Industrial / General

HealthcareLarge PharmaSpecialty BiopharmaceuticalsOncology-Focused Innovators

AboutGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.Show more

Revenue $28.75B +6.0%
EBITDA $4.43B -57.0%
Net Income $480M -91.5%
EPS (Diluted) 0.38 -91.6%
Gross Margin 78.26% +2.9%
EBITDA Margin 15.4% -59.4%
Operating Margin 5.78% -79.4%
Net Margin 1.67% -92.0%
ROE 2.29% -91.1%
ROIC 3.21% -76.7%
Debt/Equity 1.39 +26.4%
Interest Coverage 1.70 -78.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 35.8% free cash flow margin
✓10 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 16.6%
✓Healthy dividend yield of 2.6%

✗Weaknesses

✗Profits declining 38.3% over 5 years
✗Dividend payout exceeds 100% of earnings

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.45%

5Y5.08%

3Y1.74%

TTM2.78%

Profit (Net Income) CAGR

10Y-27.58%

5Y-38.34%

3Y-57.44%

TTM6336.51%

EPS CAGR

10Y-25.64%

5Y-38.21%

3Y-57.44%

TTM7066.67%

ROCE

10Y Avg20.82%

5Y Avg11.34%

3Y Avg10.58%

Latest3.4%

Peer Comparison

Oncology-Focused Innovators

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GILDGilead Sciences, Inc.	150.44B	121.26	319.11	6.04%	27.88%	37.8%	6.85%	1.39
AMGNAmgen Inc.	177.71B	330.03	43.65	18.57%	19.48%	72.82%	5.85%	10.23
CELG-RIBristol-Myers Squibb Company Ce		0.16	-0.04	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	115.26B	56.62	-12.84	7.32%	12.57%	32.47%	12.1%	3.12

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	32.64B	30.39B	26.11B	22.13B	22.45B	24.69B	27.3B	27.28B	27.12B	28.75B
Revenue Growth %	0.31%	-0.07%	-0.14%	-0.15%	0.01%	0.1%	0.11%	-0%	-0.01%	0.06%
Cost of Goods Sold+	4.01B	4.26B	4.37B	4.85B	4.67B	4.57B	6.6B	5.66B	6.5B	6.25B
COGS % of Revenue	0.12%	0.14%	0.17%	0.22%	0.21%	0.19%	0.24%	0.21%	0.24%	0.22%
Gross Profit+	28.63B	26.13B	21.74B	17.27B	17.77B	20.12B	20.7B	21.62B	20.62B	22.5B
Gross Margin %	0.88%	0.86%	0.83%	0.78%	0.79%	0.81%	0.76%	0.79%	0.76%	0.78%
Gross Profit Growth %	0.36%	-0.09%	-0.17%	-0.21%	0.03%	0.13%	0.03%	0.04%	-0.05%	0.09%
Operating Expenses+	6.44B	8.5B	7.61B	7.98B	8.44B	16.05B	10.79B	14.29B	13.01B	20.84B
OpEx % of Revenue	0.2%	0.28%	0.29%	0.36%	0.38%	0.65%	0.4%	0.52%	0.48%	0.72%
Selling, General & Admin	3.43B	3.4B	3.88B	4.06B	4.38B	5.11B	5.25B	5.67B	6.09B	6.09B
SG&A % of Revenue	0.1%	0.11%	0.15%	0.18%	0.2%	0.21%	0.19%	0.21%	0.22%	0.21%
Research & Development	3.01B	5.1B	3.73B	3.92B	4.05B	5.04B	4.6B	4.98B	5.72B	5.91B
R&D % of Revenue	0.09%	0.17%	0.14%	0.18%	0.18%	0.2%	0.17%	0.18%	0.21%	0.21%
Other Operating Expenses	0	0	0	0	0	5.89B	939M	3.64B	1.21B	8.84B
Operating Income+	22.19B	17.63B	14.12B	8.2B	4.29B	4.07B	9.92B	7.33B	7.61B	1.66B
Operating Margin %	0.68%	0.58%	0.54%	0.37%	0.19%	0.16%	0.36%	0.27%	0.28%	0.06%
Operating Income Growth %	0.45%	-0.21%	-0.2%	-0.42%	-0.48%	-0.05%	1.44%	-0.26%	0.04%	-0.78%
EBITDA+	23.29B	18.79B	15.41B	9.63B	5.69B	5.55B	11.97B	9.43B	10.3B	4.43B
EBITDA Margin %	0.71%	0.62%	0.59%	0.44%	0.25%	0.22%	0.44%	0.35%	0.38%	0.15%
EBITDA Growth %	0.43%	-0.19%	-0.18%	-0.38%	-0.41%	-0.02%	1.16%	-0.21%	0.09%	-0.57%
D&A (Non-Cash Add-back)	1.1B	1.16B	1.29B	1.43B	1.4B	1.48B	2.05B	2.1B	2.69B	2.77B
EBIT	22.35B	18.06B	14.65B	8.88B	6.16B	2.65B	9.28B	6.75B	7.8B	1.67B
Net Interest Income+	-688M	-964M	-1.12B	-1.08B	-995M	-984M	-1B	-829M	-568M	-696M
Interest Income	0	0	0	0	0	0	0	106M	376M	281M
Interest Expense	688M	964M	1.12B	1.08B	995M	984M	1B	935M	944M	977M
Other Income/Expense	-534M	-536M	-595M	-401M	873M	-2.4B	-1.64B	-1.52B	-746M	-972M
Pretax Income+	21.66B	17.1B	13.53B	7.8B	5.16B	1.67B	8.28B	5.81B	6.86B	690M
Pretax Margin %	0.66%	0.56%	0.52%	0.35%	0.23%	0.07%	0.3%	0.21%	0.25%	0.02%
Income Tax+	3.55B	3.61B	8.88B	2.34B	-204M	1.58B	2.08B	1.25B	1.25B	211M
Effective Tax Rate %	0.84%	0.79%	0.34%	0.7%	1.04%	0.07%	0.75%	0.79%	0.83%	0.7%
Net Income+	18.11B	13.5B	4.63B	5.46B	5.39B	123M	6.22B	4.59B	5.67B	480M
Net Margin %	0.55%	0.44%	0.18%	0.25%	0.24%	0%	0.23%	0.17%	0.21%	0.02%
Net Income Growth %	0.5%	-0.25%	-0.66%	0.18%	-0.01%	-0.98%	49.61%	-0.26%	0.23%	-0.92%
Net Income (Continuing)	18.11B	13.49B	4.64B	5.46B	5.36B	89M	6.2B	4.57B	5.61B	479M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	579M	476M	59M	147M	125M	19M	-5M	-31M	-84M	-84M
EPS (Diluted)+	11.91	9.94	3.51	4.17	4.22	0.10	4.93	3.64	4.50	0.38
EPS Growth %	0.62%	-0.17%	-0.65%	0.19%	0.01%	-0.98%	49.62%	-0.26%	0.24%	-0.92%
EPS (Basic)	12.37	10.08	3.54	4.20	4.24	0.10	4.96	3.66	4.54	0.38
Diluted Shares Outstanding	1.52B	1.36B	1.32B	1.31B	1.28B	1.26B	1.26B	1.26B	1.26B	1.25B
Basic Shares Outstanding	1.46B	1.34B	1.31B	1.3B	1.27B	1.26B	1.26B	1.25B	1.25B	1.25B
Dividend Payout Ratio	0.1%	0.18%	0.59%	0.54%	0.6%	28.04%	0.58%	0.81%	0.67%	8.16%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.76B	19.59B	31.82B	35.84B	30.3B	16B	14.77B	14.44B	16.09B	19.17B
Cash & Short-Term Investments	14.61B	11.89B	25.51B	30.09B	24.35B	7.41B	6.52B	6.38B	7.26B	11.57B
Cash Only	12.85B	8.23B	7.59B	17.94B	11.63B	6B	5.34B	5.41B	6.08B	9.99B
Short-Term Investments	1.76B	3.67B	17.92B	12.15B	12.72B	1.41B	1.18B	973M	1.18B	1.58B
Accounts Receivable	5.85B	4.51B	3.85B	3.33B	3.58B	4.89B	4.49B	4.78B	4.66B	4.42B
Days Sales Outstanding	65.46	54.22	53.84	54.88	58.24	72.32	60.06	63.91	62.73	56.11
Inventory	1.96B	1.59B	801M	814M	922M	1.68B	1.62B	1.51B	1.79B	1.71B
Days Inventory Outstanding	178.13	135.94	66.89	61.22	71.98	134.36	89.47	97.23	100.38	99.85
Other Current Assets	1.33B	0	0	0	0	0	0	0	2.37B	995M
Total Non-Current Assets+	26.95B	37.39B	38.46B	27.84B	31.33B	52.41B	53.18B	48.73B	46.04B	39.82B
Property, Plant & Equipment	2.28B	2.87B	3.29B	4.01B	4.5B	4.97B	5.12B	5.47B	5.32B	5.41B
Fixed Asset Turnover	14.34x	10.61x	7.92x	5.52x	4.99x	4.97x	5.33x	4.98x	5.10x	5.31x
Goodwill	1.17B	1.17B	4.16B	4.12B	4.12B	8.11B	8.33B	8.31B	8.31B	8.31B
Intangible Assets	10.25B	8.97B	17.1B	15.74B	13.79B	33.13B	33.45B	28.89B	26.45B	19.95B
Long-Term Investments	11.6B	20.48B	11.18B	1.42B	1.49B	502M	1.31B	1.25B	1.16B	0
Other Non-Current Assets	1.33B	3.49B	2.72B	2.56B	7.44B	5.71B	4.96B	4.8B	4.79B	6.15B
Total Assets+	51.72B	56.98B	70.28B	63.67B	61.63B	68.41B	67.95B	63.17B	62.13B	58.99B
Asset Turnover	0.63x	0.53x	0.37x	0.35x	0.36x	0.36x	0.40x	0.43x	0.44x	0.49x
Asset Growth %	0.49%	0.1%	0.23%	-0.09%	-0.03%	0.11%	-0.01%	-0.07%	-0.02%	-0.05%
Total Current Liabilities+	9.89B	9.22B	11.63B	10.61B	9.76B	11.4B	11.61B	11.24B	11.28B	12B
Accounts Payable	1.18B	1.21B	814M	790M	713M	844M	705M	905M	550M	833M
Days Payables Outstanding	107.33	103.31	67.97	59.42	55.67	67.38	38.98	58.39	30.89	48.64
Short-Term Debt	982M	0	2.75B	2.75B	2.5B	2.76B	1.52B	2.27B	1.8B	1.81B
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	380M	196M	455M	555M	736M	1.45B	1.43B	3.62B	3.92B	3.82B
Current Ratio	2.50x	2.12x	2.74x	3.38x	3.10x	1.40x	1.27x	1.29x	1.43x	1.60x
Quick Ratio	2.31x	1.95x	2.67x	3.30x	3.01x	1.26x	1.13x	1.15x	1.27x	1.45x
Cash Conversion Cycle	136.26	86.85	52.76	56.69	74.56	139.3	110.54	102.75	132.21	107.32
Total Non-Current Liabilities+	22.71B	28.4B	38.15B	31.54B	29.22B	38.79B	35.28B	30.72B	28.1B	27.75B
Long-Term Debt	21.07B	26.35B	30.8B	24.57B	22.09B	28.64B	25.18B	22.96B	23.19B	24.9B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	3.91B	4.36B	2.67B	1.59B	724M
Other Non-Current Liabilities	1.64B	2.05B	7.35B	6.96B	7.12B	6.23B	5.74B	5.09B	3.32B	2.13B
Total Liabilities	32.6B	37.61B	49.78B	42.14B	38.98B	50.19B	46.89B	41.96B	39.38B	39.75B
Total Debt+	22.05B	26.35B	33.54B	27.32B	24.59B	31.4B	26.7B	25.23B	24.99B	26.71B
Net Debt	9.2B	18.12B	25.95B	9.38B	12.96B	25.41B	21.36B	19.82B	18.9B	16.72B
Debt / Equity	1.15x	1.36x	1.64x	1.27x	1.09x	1.72x	1.27x	1.19x	1.10x	1.39x
Debt / EBITDA	0.95x	1.40x	2.18x	2.84x	4.32x	5.66x	2.23x	2.67x	2.43x	6.03x
Net Debt / EBITDA	0.40x	0.96x	1.68x	0.97x	2.28x	4.58x	1.78x	2.10x	1.84x	3.78x
Interest Coverage	32.26x	18.29x	12.63x	7.61x	4.31x	4.14x	9.91x	7.84x	8.06x	1.70x
Total Equity+	19.11B	19.36B	20.5B	21.53B	22.65B	18.22B	21.06B	21.21B	22.75B	19.25B
Equity Growth %	0.21%	0.01%	0.06%	0.05%	0.05%	-0.2%	0.16%	0.01%	0.07%	-0.15%
Book Value per Share	12.57	14.26	15.54	16.46	17.74	14.43	16.69	16.81	18.08	15.34
Total Shareholders' Equity	18.53B	18.89B	20.44B	21.39B	22.52B	18.2B	21.07B	21.24B	22.83B	19.33B
Common Stock	1M	1M	1M	1M	1M	1M	1M	1M	1M	1M
Retained Earnings	18B	18.15B	19.01B	19.02B	19.39B	14.38B	16.32B	15.69B	16.3B	11.5B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	88M	278M	165M	80M	85M	-60M	83M	2M	28M	132M
Minority Interest	579M	476M	59M	147M	125M	19M	-5M	-31M	-84M	-84M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.25B	17.05B	11.9B	8.4B	9.14B	8.17B	11.38B	9.07B	8.01B	10.83B
Operating CF Margin %	0.65%	0.56%	0.46%	0.38%	0.41%	0.33%	0.42%	0.33%	0.3%	0.38%
Operating CF Growth %	0.66%	-0.2%	-0.3%	-0.29%	0.09%	-0.11%	0.39%	-0.2%	-0.12%	0.35%
Net Income	18.11B	13.49B	4.64B	5.46B	5.36B	123M	6.2B	4.59B	5.67B	480M
Depreciation & Amortization	1.1B	1.16B	1.29B	1.43B	1.4B	1.48B	2.05B	2.1B	2.69B	2.77B
Stock-Based Compensation	382M	380M	638M	845M	636M	643M	635M	644M	766M	835M
Deferred Taxes	-393M	-119M	-82M	289M	-2.1B	-214M	-116M	-1.55B	-962M	-1.84B
Other Non-Cash Items	562M	594M	304M	1.32B	4.64B	7.77B	2.13B	5.05B	2.15B	9.47B
Working Capital Changes	1.5B	1.55B	5.11B	-939M	-798M	-1.64B	489M	-1.76B	-2.3B	-880M
Change in Receivables	-1.4B	1.19B	754M	480M	-218M	-1.17B	313M	-406M	157M	139M
Change in Inventory	-855M	-488M	-253M	-310M	-95M	-195M	11M	-310M	-842M	-426M
Change in Payables	226M	47M	-430M	-39M	-61M	80M	-118M	226M	-347M	290M
Cash from Investing+	-12.47B	-11.98B	-16.07B	14.36B	-7.82B	-14.62B	-3.13B	-2.47B	-2.27B	-3.45B
Capital Expenditures	-747M	-748M	-590M	-924M	-825M	-650M	-579M	-728M	-585M	-523M
CapEx % of Revenue	0.02%	0.02%	0.02%	0.04%	0.04%	0.03%	0.02%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-190M	-434M	-171M	19M	-1M	0	58M
Cash from Financing+	-5.88B	-9.72B	3.39B	-12.32B	-7.63B	770M	-8.88B	-6.47B	-5.13B	-3.43B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.87B	-2.46B	-2.73B	-2.97B	-3.22B	-3.45B	-3.6B	-3.71B	-3.81B	-3.92B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-4.02B	-745M	-330M	-486M	-122M	-138M	-145M	-173M	-278M	-281M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	20.5B	16.3B	11.31B	7.48B	8.32B	7.52B	10.8B	8.34B	7.42B	10.3B
FCF Margin %	0.63%	0.54%	0.43%	0.34%	0.37%	0.3%	0.4%	0.31%	0.27%	0.36%
FCF Growth %	0.67%	-0.21%	-0.31%	-0.34%	0.11%	-0.1%	0.44%	-0.23%	-0.11%	0.39%
FCF per Share	13.48	12.00	8.57	5.72	6.51	5.95	8.56	6.61	5.90	8.21
FCF Conversion (FCF/Net Income)	1.17x	1.26x	2.57x	1.54x	1.70x	66.41x	1.83x	1.98x	1.41x	22.56x
Interest Paid	529M	885M	1.04B	1.07B	982M	951M	979M	907M	891M	951M
Taxes Paid	3.14B	2.44B	3.34B	3.2B	1.79B	2.64B	2.51B	3.14B	3.99B	2.78B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	103.68%	70.18%	23.22%	25.95%	24.38%	0.6%	31.69%	21.73%	25.77%	2.29%
Return on Invested Capital (ROIC)	71.57%	40.2%	25.24%	15.9%	9.67%	7.71%	17.29%	13.18%	13.8%	3.21%
Gross Margin	87.73%	85.98%	83.26%	78.07%	79.17%	81.48%	75.82%	79.26%	76.04%	78.26%
Net Margin	55.48%	44.43%	17.73%	24.65%	23.99%	0.5%	22.8%	16.83%	20.89%	1.67%
Debt / Equity	1.15x	1.36x	1.64x	1.27x	1.09x	1.72x	1.27x	1.19x	1.10x	1.39x
Interest Coverage	32.26x	18.29x	12.63x	7.61x	4.31x	4.14x	9.91x	7.84x	8.06x	1.70x
FCF Conversion	1.17x	1.26x	2.57x	1.54x	1.70x	66.41x	1.83x	1.98x	1.41x	22.56x
Revenue Growth	31.13%	-6.89%	-14.09%	-15.25%	1.46%	9.98%	10.6%	-0.09%	-0.6%	6.04%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Products, Other HIV	-	-	-	61M	47M	17B	16.36B	17.25B	18.23B	19.61B
Products, Other HIV Growth	-	-	-	-	-22.95%	36061.70%	-3.71%	5.41%	5.68%	7.58%
Cell Therapy Products, Total Cell Therapy Product Sales	-	-	-	-	-	607M	1.05B	1.76B	2.24B	2.38B
Cell Therapy Products, Total Cell Therapy Product Sales Growth	-	-	-	-	-	-	72.49%	67.91%	27.36%	6.12%
Veklury	-	-	-	-	-	-	5.57B	3.9B	2.18B	1.8B
Veklury Growth	-	-	-	-	-	-	-	-29.83%	-44.07%	-17.63%
Trodelvy	-	-	-	-	-	-	380M	680M	1.06B	1.31B
Trodelvy Growth	-	-	-	-	-	-	-	78.95%	56.32%	23.71%
Other Products, Total Other product sales	-	-	-	-	-	1.89B	1.03B	946M	859M	889M
Other Products, Total Other product sales Growth	-	-	-	-	-	-	-45.55%	-7.89%	-9.20%	3.49%
Hepatitis B Virus / Hepatitis Delta Virus Product	-	-	-	-	-	-	969M	988M	1.02B	-
Hepatitis B Virus / Hepatitis Delta Virus Product Growth	-	-	-	-	-	-	-	1.96%	2.94%	-
Antiviral Products	30.21B	27.75B	23.34B	-	-	-	-	-	-	-
Antiviral Products Growth	-	-8.15%	-15.89%	-	-	-	-	-	-	-
Harvoni	13.86B	9.08B	4.37B	-	-	-	-	-	-	-
Harvoni Growth	-	-34.50%	-51.88%	-	-	-	-	-	-	-
Genvoya	45M	1.48B	3.67B	-	-	-	-	-	-	-
Genvoya Growth	-	3197.78%	147.57%	-	-	-	-	-	-	-
Epclusa	-	1.75B	3.51B	-	-	-	-	-	-	-
Epclusa Growth	-	-	100.34%	-	-	-	-	-	-	-
Truvada	3.46B	3.57B	3.13B	-	-	-	-	-	-	-
Truvada Growth	-	3.09%	-12.11%	-	-	-	-	-	-	-
Atripla	3.13B	2.6B	1.81B	-	-	-	-	-	-	-
Atripla Growth	-	-16.88%	-30.67%	-	-	-	-	-	-	-
Descovy	-	298M	1.22B	-	-	-	-	-	-	-
Descovy Growth	-	-	308.72%	-	-	-	-	-	-	-
Odefsey	-	329M	1.11B	-	-	-	-	-	-	-
Odefsey Growth	-	-	236.17%	-	-	-	-	-	-	-
Stribild	1.82B	1.91B	1.05B	-	-	-	-	-	-	-
Stribild Growth	-	4.88%	-44.98%	-	-	-	-	-	-	-
Viread	1.11B	1.19B	1.05B	-	-	-	-	-	-	-
Viread Growth	-	7.04%	-11.80%	-	-	-	-	-	-	-
Complera Eviplera	1.43B	1.46B	966M	-	-	-	-	-	-	-
Complera Eviplera Growth	-	2.10%	-33.70%	-	-	-	-	-	-	-
Sovaldi	5.28B	4B	964M	-	-	-	-	-	-	-
Sovaldi Growth	-	-24.17%	-75.91%	-	-	-	-	-	-	-
Letairis	700M	819M	887M	-	-	-	-	-	-	-
Letairis Growth	-	17.00%	8.30%	-	-	-	-	-	-	-
Ranexa	588M	677M	717M	-	-	-	-	-	-	-
Ranexa Growth	-	15.14%	5.91%	-	-	-	-	-	-	-
Ambisome	350M	356M	366M	-	-	-	-	-	-	-
Ambisome Growth	-	1.71%	2.81%	-	-	-	-	-	-	-
Vosevi	-	-	293M	-	-	-	-	-	-	-
Vosevi Growth	-	-	-	-	-	-	-	-	-	-
Other Products	174M	188M	207M	-	-	-	-	-	-	-
Other Products Growth	-	8.05%	10.11%	-	-	-	-	-	-	-
Other antiviral products	69M	72M	196M	-	-	-	-	-	-	-
Other antiviral products Growth	-	4.35%	172.22%	-	-	-	-	-	-	-
Zydelig	132M	168M	149M	-	-	-	-	-	-	-
Zydelig Growth	-	27.27%	-11.31%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	21.23B	19.35B	18.19B	16.27B	16.64B	18.22B	19.27B	18.88B	19.44B	20.59B
UNITED STATES Growth	-	-8.85%	-5.99%	-10.58%	2.31%	9.44%	5.76%	-1.99%	2.93%	5.93%
Europe	7.53B	6.37B	5.31B	4.01B	3.81B	4.13B	4.87B	4.47B	4.31B	4.63B
Europe Growth	-	-15.45%	-16.56%	-24.57%	-4.87%	8.50%	17.87%	-8.31%	-3.56%	7.52%
Other International	3.88B	2.14B	2.6B	1.85B	1.99B	2.34B	3.16B	3.93B	3.37B	3.53B
Other International Growth	-	-44.70%	21.36%	-28.82%	7.61%	17.26%	35.39%	24.15%	-14.26%	4.78%
JAPAN	-	2.53B	-	-	-	-	-	-	-	-
JAPAN Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Gilead Sciences, Inc. (GILD) has a price-to-earnings (P/E) ratio of 319.1x. This suggests investors expect higher future growth.

Growth & Financials

Gilead Sciences, Inc. (GILD) reported $29.09B in revenue for fiscal year 2024. This represents a 247% increase from $8.39B in 2011.

Gilead Sciences, Inc. (GILD) grew revenue by 6.0% over the past year. This is steady growth.

Yes, Gilead Sciences, Inc. (GILD) is profitable, generating $8.11B in net income for fiscal year 2024 (1.7% net margin).

Dividend & Returns

Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a yield of 2.57%. This makes it attractive for income-focused investors.

Gilead Sciences, Inc. (GILD) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.

Gilead Sciences, Inc. (GILD) generated $9.16B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Gilead Sciences, Inc. (GILD) 10-Year Financial Performance & Capital Metrics

GILD • • Industrial / General

HealthcareLarge PharmaSpecialty BiopharmaceuticalsOncology-Focused Innovators

Revenue $28.75B +6.0%
EBITDA $4.43B -57.0%
Net Income $480M -91.5%
EPS (Diluted) 0.38 -91.6%
Gross Margin 78.26% +2.9%
EBITDA Margin 15.4% -59.4%
Operating Margin 5.78% -79.4%
Net Margin 1.67% -92.0%
ROE 2.29% -91.1%
ROIC 3.21% -76.7%
Debt/Equity 1.39 +26.4%
Interest Coverage 1.70 -78.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 35.8% free cash flow margin
✓10 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 16.6%
✓Healthy dividend yield of 2.6%

✗Weaknesses

✗Profits declining 38.3% over 5 years
✗Dividend payout exceeds 100% of earnings

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.45%

5Y5.08%

3Y1.74%

TTM2.78%

Profit (Net Income) CAGR

10Y-27.58%

5Y-38.34%

3Y-57.44%

TTM6336.51%

EPS CAGR

10Y-25.64%

5Y-38.21%

3Y-57.44%

TTM7066.67%

ROCE

10Y Avg20.82%

5Y Avg11.34%

3Y Avg10.58%

Latest3.4%

Peer Comparison

Oncology-Focused Innovators

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GILDGilead Sciences, Inc.	150.44B	121.26	319.11	6.04%	27.88%	37.8%	6.85%	1.39
AMGNAmgen Inc.	177.71B	330.03	43.65	18.57%	19.48%	72.82%	5.85%	10.23
CELG-RIBristol-Myers Squibb Company Ce		0.16	-0.04	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	115.26B	56.62	-12.84	7.32%	12.57%	32.47%	12.1%	3.12

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	32.64B	30.39B	26.11B	22.13B	22.45B	24.69B	27.3B	27.28B	27.12B	28.75B
Revenue Growth %	0.31%	-0.07%	-0.14%	-0.15%	0.01%	0.1%	0.11%	-0%	-0.01%	0.06%
Cost of Goods Sold+	4.01B	4.26B	4.37B	4.85B	4.67B	4.57B	6.6B	5.66B	6.5B	6.25B
COGS % of Revenue	0.12%	0.14%	0.17%	0.22%	0.21%	0.19%	0.24%	0.21%	0.24%	0.22%
Gross Profit+	28.63B	26.13B	21.74B	17.27B	17.77B	20.12B	20.7B	21.62B	20.62B	22.5B
Gross Margin %	0.88%	0.86%	0.83%	0.78%	0.79%	0.81%	0.76%	0.79%	0.76%	0.78%
Gross Profit Growth %	0.36%	-0.09%	-0.17%	-0.21%	0.03%	0.13%	0.03%	0.04%	-0.05%	0.09%
Operating Expenses+	6.44B	8.5B	7.61B	7.98B	8.44B	16.05B	10.79B	14.29B	13.01B	20.84B
OpEx % of Revenue	0.2%	0.28%	0.29%	0.36%	0.38%	0.65%	0.4%	0.52%	0.48%	0.72%
Selling, General & Admin	3.43B	3.4B	3.88B	4.06B	4.38B	5.11B	5.25B	5.67B	6.09B	6.09B
SG&A % of Revenue	0.1%	0.11%	0.15%	0.18%	0.2%	0.21%	0.19%	0.21%	0.22%	0.21%
Research & Development	3.01B	5.1B	3.73B	3.92B	4.05B	5.04B	4.6B	4.98B	5.72B	5.91B
R&D % of Revenue	0.09%	0.17%	0.14%	0.18%	0.18%	0.2%	0.17%	0.18%	0.21%	0.21%
Other Operating Expenses	0	0	0	0	0	5.89B	939M	3.64B	1.21B	8.84B
Operating Income+	22.19B	17.63B	14.12B	8.2B	4.29B	4.07B	9.92B	7.33B	7.61B	1.66B
Operating Margin %	0.68%	0.58%	0.54%	0.37%	0.19%	0.16%	0.36%	0.27%	0.28%	0.06%
Operating Income Growth %	0.45%	-0.21%	-0.2%	-0.42%	-0.48%	-0.05%	1.44%	-0.26%	0.04%	-0.78%
EBITDA+	23.29B	18.79B	15.41B	9.63B	5.69B	5.55B	11.97B	9.43B	10.3B	4.43B
EBITDA Margin %	0.71%	0.62%	0.59%	0.44%	0.25%	0.22%	0.44%	0.35%	0.38%	0.15%
EBITDA Growth %	0.43%	-0.19%	-0.18%	-0.38%	-0.41%	-0.02%	1.16%	-0.21%	0.09%	-0.57%
D&A (Non-Cash Add-back)	1.1B	1.16B	1.29B	1.43B	1.4B	1.48B	2.05B	2.1B	2.69B	2.77B
EBIT	22.35B	18.06B	14.65B	8.88B	6.16B	2.65B	9.28B	6.75B	7.8B	1.67B
Net Interest Income+	-688M	-964M	-1.12B	-1.08B	-995M	-984M	-1B	-829M	-568M	-696M
Interest Income	0	0	0	0	0	0	0	106M	376M	281M
Interest Expense	688M	964M	1.12B	1.08B	995M	984M	1B	935M	944M	977M
Other Income/Expense	-534M	-536M	-595M	-401M	873M	-2.4B	-1.64B	-1.52B	-746M	-972M
Pretax Income+	21.66B	17.1B	13.53B	7.8B	5.16B	1.67B	8.28B	5.81B	6.86B	690M
Pretax Margin %	0.66%	0.56%	0.52%	0.35%	0.23%	0.07%	0.3%	0.21%	0.25%	0.02%
Income Tax+	3.55B	3.61B	8.88B	2.34B	-204M	1.58B	2.08B	1.25B	1.25B	211M
Effective Tax Rate %	0.84%	0.79%	0.34%	0.7%	1.04%	0.07%	0.75%	0.79%	0.83%	0.7%
Net Income+	18.11B	13.5B	4.63B	5.46B	5.39B	123M	6.22B	4.59B	5.67B	480M
Net Margin %	0.55%	0.44%	0.18%	0.25%	0.24%	0%	0.23%	0.17%	0.21%	0.02%
Net Income Growth %	0.5%	-0.25%	-0.66%	0.18%	-0.01%	-0.98%	49.61%	-0.26%	0.23%	-0.92%
Net Income (Continuing)	18.11B	13.49B	4.64B	5.46B	5.36B	89M	6.2B	4.57B	5.61B	479M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	579M	476M	59M	147M	125M	19M	-5M	-31M	-84M	-84M
EPS (Diluted)+	11.91	9.94	3.51	4.17	4.22	0.10	4.93	3.64	4.50	0.38
EPS Growth %	0.62%	-0.17%	-0.65%	0.19%	0.01%	-0.98%	49.62%	-0.26%	0.24%	-0.92%
EPS (Basic)	12.37	10.08	3.54	4.20	4.24	0.10	4.96	3.66	4.54	0.38
Diluted Shares Outstanding	1.52B	1.36B	1.32B	1.31B	1.28B	1.26B	1.26B	1.26B	1.26B	1.25B
Basic Shares Outstanding	1.46B	1.34B	1.31B	1.3B	1.27B	1.26B	1.26B	1.25B	1.25B	1.25B
Dividend Payout Ratio	0.1%	0.18%	0.59%	0.54%	0.6%	28.04%	0.58%	0.81%	0.67%	8.16%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	24.76B	19.59B	31.82B	35.84B	30.3B	16B	14.77B	14.44B	16.09B	19.17B
Cash & Short-Term Investments	14.61B	11.89B	25.51B	30.09B	24.35B	7.41B	6.52B	6.38B	7.26B	11.57B
Cash Only	12.85B	8.23B	7.59B	17.94B	11.63B	6B	5.34B	5.41B	6.08B	9.99B
Short-Term Investments	1.76B	3.67B	17.92B	12.15B	12.72B	1.41B	1.18B	973M	1.18B	1.58B
Accounts Receivable	5.85B	4.51B	3.85B	3.33B	3.58B	4.89B	4.49B	4.78B	4.66B	4.42B
Days Sales Outstanding	65.46	54.22	53.84	54.88	58.24	72.32	60.06	63.91	62.73	56.11
Inventory	1.96B	1.59B	801M	814M	922M	1.68B	1.62B	1.51B	1.79B	1.71B
Days Inventory Outstanding	178.13	135.94	66.89	61.22	71.98	134.36	89.47	97.23	100.38	99.85
Other Current Assets	1.33B	0	0	0	0	0	0	0	2.37B	995M
Total Non-Current Assets+	26.95B	37.39B	38.46B	27.84B	31.33B	52.41B	53.18B	48.73B	46.04B	39.82B
Property, Plant & Equipment	2.28B	2.87B	3.29B	4.01B	4.5B	4.97B	5.12B	5.47B	5.32B	5.41B
Fixed Asset Turnover	14.34x	10.61x	7.92x	5.52x	4.99x	4.97x	5.33x	4.98x	5.10x	5.31x
Goodwill	1.17B	1.17B	4.16B	4.12B	4.12B	8.11B	8.33B	8.31B	8.31B	8.31B
Intangible Assets	10.25B	8.97B	17.1B	15.74B	13.79B	33.13B	33.45B	28.89B	26.45B	19.95B
Long-Term Investments	11.6B	20.48B	11.18B	1.42B	1.49B	502M	1.31B	1.25B	1.16B	0
Other Non-Current Assets	1.33B	3.49B	2.72B	2.56B	7.44B	5.71B	4.96B	4.8B	4.79B	6.15B
Total Assets+	51.72B	56.98B	70.28B	63.67B	61.63B	68.41B	67.95B	63.17B	62.13B	58.99B
Asset Turnover	0.63x	0.53x	0.37x	0.35x	0.36x	0.36x	0.40x	0.43x	0.44x	0.49x
Asset Growth %	0.49%	0.1%	0.23%	-0.09%	-0.03%	0.11%	-0.01%	-0.07%	-0.02%	-0.05%
Total Current Liabilities+	9.89B	9.22B	11.63B	10.61B	9.76B	11.4B	11.61B	11.24B	11.28B	12B
Accounts Payable	1.18B	1.21B	814M	790M	713M	844M	705M	905M	550M	833M
Days Payables Outstanding	107.33	103.31	67.97	59.42	55.67	67.38	38.98	58.39	30.89	48.64
Short-Term Debt	982M	0	2.75B	2.75B	2.5B	2.76B	1.52B	2.27B	1.8B	1.81B
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	380M	196M	455M	555M	736M	1.45B	1.43B	3.62B	3.92B	3.82B
Current Ratio	2.50x	2.12x	2.74x	3.38x	3.10x	1.40x	1.27x	1.29x	1.43x	1.60x
Quick Ratio	2.31x	1.95x	2.67x	3.30x	3.01x	1.26x	1.13x	1.15x	1.27x	1.45x
Cash Conversion Cycle	136.26	86.85	52.76	56.69	74.56	139.3	110.54	102.75	132.21	107.32
Total Non-Current Liabilities+	22.71B	28.4B	38.15B	31.54B	29.22B	38.79B	35.28B	30.72B	28.1B	27.75B
Long-Term Debt	21.07B	26.35B	30.8B	24.57B	22.09B	28.64B	25.18B	22.96B	23.19B	24.9B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	3.91B	4.36B	2.67B	1.59B	724M
Other Non-Current Liabilities	1.64B	2.05B	7.35B	6.96B	7.12B	6.23B	5.74B	5.09B	3.32B	2.13B
Total Liabilities	32.6B	37.61B	49.78B	42.14B	38.98B	50.19B	46.89B	41.96B	39.38B	39.75B
Total Debt+	22.05B	26.35B	33.54B	27.32B	24.59B	31.4B	26.7B	25.23B	24.99B	26.71B
Net Debt	9.2B	18.12B	25.95B	9.38B	12.96B	25.41B	21.36B	19.82B	18.9B	16.72B
Debt / Equity	1.15x	1.36x	1.64x	1.27x	1.09x	1.72x	1.27x	1.19x	1.10x	1.39x
Debt / EBITDA	0.95x	1.40x	2.18x	2.84x	4.32x	5.66x	2.23x	2.67x	2.43x	6.03x
Net Debt / EBITDA	0.40x	0.96x	1.68x	0.97x	2.28x	4.58x	1.78x	2.10x	1.84x	3.78x
Interest Coverage	32.26x	18.29x	12.63x	7.61x	4.31x	4.14x	9.91x	7.84x	8.06x	1.70x
Total Equity+	19.11B	19.36B	20.5B	21.53B	22.65B	18.22B	21.06B	21.21B	22.75B	19.25B
Equity Growth %	0.21%	0.01%	0.06%	0.05%	0.05%	-0.2%	0.16%	0.01%	0.07%	-0.15%
Book Value per Share	12.57	14.26	15.54	16.46	17.74	14.43	16.69	16.81	18.08	15.34
Total Shareholders' Equity	18.53B	18.89B	20.44B	21.39B	22.52B	18.2B	21.07B	21.24B	22.83B	19.33B
Common Stock	1M	1M	1M	1M	1M	1M	1M	1M	1M	1M
Retained Earnings	18B	18.15B	19.01B	19.02B	19.39B	14.38B	16.32B	15.69B	16.3B	11.5B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	88M	278M	165M	80M	85M	-60M	83M	2M	28M	132M
Minority Interest	579M	476M	59M	147M	125M	19M	-5M	-31M	-84M	-84M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.25B	17.05B	11.9B	8.4B	9.14B	8.17B	11.38B	9.07B	8.01B	10.83B
Operating CF Margin %	0.65%	0.56%	0.46%	0.38%	0.41%	0.33%	0.42%	0.33%	0.3%	0.38%
Operating CF Growth %	0.66%	-0.2%	-0.3%	-0.29%	0.09%	-0.11%	0.39%	-0.2%	-0.12%	0.35%
Net Income	18.11B	13.49B	4.64B	5.46B	5.36B	123M	6.2B	4.59B	5.67B	480M
Depreciation & Amortization	1.1B	1.16B	1.29B	1.43B	1.4B	1.48B	2.05B	2.1B	2.69B	2.77B
Stock-Based Compensation	382M	380M	638M	845M	636M	643M	635M	644M	766M	835M
Deferred Taxes	-393M	-119M	-82M	289M	-2.1B	-214M	-116M	-1.55B	-962M	-1.84B
Other Non-Cash Items	562M	594M	304M	1.32B	4.64B	7.77B	2.13B	5.05B	2.15B	9.47B
Working Capital Changes	1.5B	1.55B	5.11B	-939M	-798M	-1.64B	489M	-1.76B	-2.3B	-880M
Change in Receivables	-1.4B	1.19B	754M	480M	-218M	-1.17B	313M	-406M	157M	139M
Change in Inventory	-855M	-488M	-253M	-310M	-95M	-195M	11M	-310M	-842M	-426M
Change in Payables	226M	47M	-430M	-39M	-61M	80M	-118M	226M	-347M	290M
Cash from Investing+	-12.47B	-11.98B	-16.07B	14.36B	-7.82B	-14.62B	-3.13B	-2.47B	-2.27B	-3.45B
Capital Expenditures	-747M	-748M	-590M	-924M	-825M	-650M	-579M	-728M	-585M	-523M
CapEx % of Revenue	0.02%	0.02%	0.02%	0.04%	0.04%	0.03%	0.02%	0.03%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-190M	-434M	-171M	19M	-1M	0	58M
Cash from Financing+	-5.88B	-9.72B	3.39B	-12.32B	-7.63B	770M	-8.88B	-6.47B	-5.13B	-3.43B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.87B	-2.46B	-2.73B	-2.97B	-3.22B	-3.45B	-3.6B	-3.71B	-3.81B	-3.92B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-4.02B	-745M	-330M	-486M	-122M	-138M	-145M	-173M	-278M	-281M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	20.5B	16.3B	11.31B	7.48B	8.32B	7.52B	10.8B	8.34B	7.42B	10.3B
FCF Margin %	0.63%	0.54%	0.43%	0.34%	0.37%	0.3%	0.4%	0.31%	0.27%	0.36%
FCF Growth %	0.67%	-0.21%	-0.31%	-0.34%	0.11%	-0.1%	0.44%	-0.23%	-0.11%	0.39%
FCF per Share	13.48	12.00	8.57	5.72	6.51	5.95	8.56	6.61	5.90	8.21
FCF Conversion (FCF/Net Income)	1.17x	1.26x	2.57x	1.54x	1.70x	66.41x	1.83x	1.98x	1.41x	22.56x
Interest Paid	529M	885M	1.04B	1.07B	982M	951M	979M	907M	891M	951M
Taxes Paid	3.14B	2.44B	3.34B	3.2B	1.79B	2.64B	2.51B	3.14B	3.99B	2.78B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	103.68%	70.18%	23.22%	25.95%	24.38%	0.6%	31.69%	21.73%	25.77%	2.29%
Return on Invested Capital (ROIC)	71.57%	40.2%	25.24%	15.9%	9.67%	7.71%	17.29%	13.18%	13.8%	3.21%
Gross Margin	87.73%	85.98%	83.26%	78.07%	79.17%	81.48%	75.82%	79.26%	76.04%	78.26%
Net Margin	55.48%	44.43%	17.73%	24.65%	23.99%	0.5%	22.8%	16.83%	20.89%	1.67%
Debt / Equity	1.15x	1.36x	1.64x	1.27x	1.09x	1.72x	1.27x	1.19x	1.10x	1.39x
Interest Coverage	32.26x	18.29x	12.63x	7.61x	4.31x	4.14x	9.91x	7.84x	8.06x	1.70x
FCF Conversion	1.17x	1.26x	2.57x	1.54x	1.70x	66.41x	1.83x	1.98x	1.41x	22.56x
Revenue Growth	31.13%	-6.89%	-14.09%	-15.25%	1.46%	9.98%	10.6%	-0.09%	-0.6%	6.04%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Products, Other HIV	-	-	-	61M	47M	17B	16.36B	17.25B	18.23B	19.61B
Products, Other HIV Growth	-	-	-	-	-22.95%	36061.70%	-3.71%	5.41%	5.68%	7.58%
Cell Therapy Products, Total Cell Therapy Product Sales	-	-	-	-	-	607M	1.05B	1.76B	2.24B	2.38B
Cell Therapy Products, Total Cell Therapy Product Sales Growth	-	-	-	-	-	-	72.49%	67.91%	27.36%	6.12%
Veklury	-	-	-	-	-	-	5.57B	3.9B	2.18B	1.8B
Veklury Growth	-	-	-	-	-	-	-	-29.83%	-44.07%	-17.63%
Trodelvy	-	-	-	-	-	-	380M	680M	1.06B	1.31B
Trodelvy Growth	-	-	-	-	-	-	-	78.95%	56.32%	23.71%
Other Products, Total Other product sales	-	-	-	-	-	1.89B	1.03B	946M	859M	889M
Other Products, Total Other product sales Growth	-	-	-	-	-	-	-45.55%	-7.89%	-9.20%	3.49%
Hepatitis B Virus / Hepatitis Delta Virus Product	-	-	-	-	-	-	969M	988M	1.02B	-
Hepatitis B Virus / Hepatitis Delta Virus Product Growth	-	-	-	-	-	-	-	1.96%	2.94%	-
Antiviral Products	30.21B	27.75B	23.34B	-	-	-	-	-	-	-
Antiviral Products Growth	-	-8.15%	-15.89%	-	-	-	-	-	-	-
Harvoni	13.86B	9.08B	4.37B	-	-	-	-	-	-	-
Harvoni Growth	-	-34.50%	-51.88%	-	-	-	-	-	-	-
Genvoya	45M	1.48B	3.67B	-	-	-	-	-	-	-
Genvoya Growth	-	3197.78%	147.57%	-	-	-	-	-	-	-
Epclusa	-	1.75B	3.51B	-	-	-	-	-	-	-
Epclusa Growth	-	-	100.34%	-	-	-	-	-	-	-
Truvada	3.46B	3.57B	3.13B	-	-	-	-	-	-	-
Truvada Growth	-	3.09%	-12.11%	-	-	-	-	-	-	-
Atripla	3.13B	2.6B	1.81B	-	-	-	-	-	-	-
Atripla Growth	-	-16.88%	-30.67%	-	-	-	-	-	-	-
Descovy	-	298M	1.22B	-	-	-	-	-	-	-
Descovy Growth	-	-	308.72%	-	-	-	-	-	-	-
Odefsey	-	329M	1.11B	-	-	-	-	-	-	-
Odefsey Growth	-	-	236.17%	-	-	-	-	-	-	-
Stribild	1.82B	1.91B	1.05B	-	-	-	-	-	-	-
Stribild Growth	-	4.88%	-44.98%	-	-	-	-	-	-	-
Viread	1.11B	1.19B	1.05B	-	-	-	-	-	-	-
Viread Growth	-	7.04%	-11.80%	-	-	-	-	-	-	-
Complera Eviplera	1.43B	1.46B	966M	-	-	-	-	-	-	-
Complera Eviplera Growth	-	2.10%	-33.70%	-	-	-	-	-	-	-
Sovaldi	5.28B	4B	964M	-	-	-	-	-	-	-
Sovaldi Growth	-	-24.17%	-75.91%	-	-	-	-	-	-	-
Letairis	700M	819M	887M	-	-	-	-	-	-	-
Letairis Growth	-	17.00%	8.30%	-	-	-	-	-	-	-
Ranexa	588M	677M	717M	-	-	-	-	-	-	-
Ranexa Growth	-	15.14%	5.91%	-	-	-	-	-	-	-
Ambisome	350M	356M	366M	-	-	-	-	-	-	-
Ambisome Growth	-	1.71%	2.81%	-	-	-	-	-	-	-
Vosevi	-	-	293M	-	-	-	-	-	-	-
Vosevi Growth	-	-	-	-	-	-	-	-	-	-
Other Products	174M	188M	207M	-	-	-	-	-	-	-
Other Products Growth	-	8.05%	10.11%	-	-	-	-	-	-	-
Other antiviral products	69M	72M	196M	-	-	-	-	-	-	-
Other antiviral products Growth	-	4.35%	172.22%	-	-	-	-	-	-	-
Zydelig	132M	168M	149M	-	-	-	-	-	-	-
Zydelig Growth	-	27.27%	-11.31%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	21.23B	19.35B	18.19B	16.27B	16.64B	18.22B	19.27B	18.88B	19.44B	20.59B
UNITED STATES Growth	-	-8.85%	-5.99%	-10.58%	2.31%	9.44%	5.76%	-1.99%	2.93%	5.93%
Europe	7.53B	6.37B	5.31B	4.01B	3.81B	4.13B	4.87B	4.47B	4.31B	4.63B
Europe Growth	-	-15.45%	-16.56%	-24.57%	-4.87%	8.50%	17.87%	-8.31%	-3.56%	7.52%
Other International	3.88B	2.14B	2.6B	1.85B	1.99B	2.34B	3.16B	3.93B	3.37B	3.53B
Other International Growth	-	-44.70%	21.36%	-28.82%	7.61%	17.26%	35.39%	24.15%	-14.26%	4.78%
JAPAN	-	2.53B	-	-	-	-	-	-	-	-
JAPAN Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Gilead Sciences, Inc. (GILD) has a price-to-earnings (P/E) ratio of 319.1x. This suggests investors expect higher future growth.

Growth & Financials

Gilead Sciences, Inc. (GILD) reported $29.09B in revenue for fiscal year 2024. This represents a 247% increase from $8.39B in 2011.

Gilead Sciences, Inc. (GILD) grew revenue by 6.0% over the past year. This is steady growth.

Yes, Gilead Sciences, Inc. (GILD) is profitable, generating $8.11B in net income for fiscal year 2024 (1.7% net margin).

Dividend & Returns

Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a yield of 2.57%. This makes it attractive for income-focused investors.

Gilead Sciences, Inc. (GILD) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.

Gilead Sciences, Inc. (GILD) generated $9.16B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.